Ana Radeljevic
Directeur/Membre du Conseil chez MERRIMACK PHARMACEUTICALS, INC.
Fortune : 61 218 $ au 30/04/2024
Profil
Ana Radeljevic is currently the Chief Executive Officer at Adventus Partners since 2016.
She is also an Independent Director at Merrimack Pharmaceuticals, Inc. since 2022 and the Chief Business Officer at ADRx, Inc. since 2021.
Previously, she worked as the Vice President-Financial Planning & Analysis at Revvity, Inc. from 2014 to 2016.
Ms. Radeljevic holds an MBA from Syracuse University and an undergraduate degree from Old Dominion University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/03/2024 | 4 156 ( 0,03% ) | 61 218 $ | 30/04/2024 |
Postes actifs de Ana Radeljevic
| Sociétés | Poste | Début |
|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 06/06/2022 |
ADRx, Inc.
 ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/09/2021 |
Anciens postes connus de Ana Radeljevic
| Sociétés | Poste | Fin |
|---|---|---|
| REVVITY, INC. | Corporate Officer/Principal | 01/01/2016 |
Formation de Ana Radeljevic
| Syracuse University | Masters Business Admin |
| Old Dominion University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| REVVITY, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
ADRx, Inc.
ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Health Technology |